NOVAVAX COVID-19 vaccine: Has 90% efficacy against COVID
On 14th June 2021, The US Biotechnology Company NOVAVAX has made an announcement that its COVID-19 vaccine named NOVAVAX has resulted 100% protection against the moderate and severe symptoms of the Covid-19 disease and has also shown 90.4 (%) percent efficacy overall in phase 3 trials.
NEW DATA RELEASE: Novavax #COVID19 Vaccine Demonstrates 90% Overall Efficacy and 100% Protection Against Moderate and Severe Disease in PREVENT-19 Phase 3 Trial https://t.co/lIOiQXxDtD pic.twitter.com/4ePHxDpziZ— Novavax (@Novavax) June 14, 2021
What is NOVAVAX COVID-19 (Corona) vaccine:
- NOVAVAX COVID-19 vaccine (NVX-CoV2373) is known as a protein-based vaccine and made from the genetic sequence of the first strain of SARS-CoV-2.
- NOVAVAX received enrollments of 29,960 participants across 119 sites in the United States and Mexico to examine the safety, efficacy, and immunogenicity of the vaccine.